Ebola Virus
Conditions
Brief summary
Ebola virus has infected and killed people, mostly in Africa. In 2014, the Ebola virus has affected several thousand people. There is no approved effective way to treat or prevent Ebola. Researchers are trying to develop a vaccine for it. This is a study of the anti-Ebola vaccine BPSC-1001 to see if it is safe and to see how it affects people's immune system.
Detailed description
Between 1994 and the present, there have been many Ebola viruses (EBOV) outbreaks affecting mostly central Africa. However, the 2014 West African outbreak significantly exceeds all previous outbreaks in geographic range, number of individuals affected and in disruption of typical activities of civil society. This is a Phase 1 safety and tolerability study to evaluate a novel vaccine to Ebola using a live replicating vesicular stomatitis virus (VSV) replacing the gene encoding the G envelope glycoprotein with the gene encoding the envelope glycoprotein from the Zaire strain of Ebola (VSVΔG-ZEBOV also known as V920 and BPSC-1001).
Interventions
BIOLOGICALV920 Vaccine
Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10\^3, 3x10\^4, 3x10\^5, 3x10\^6, 9x10\^6, 2x10\^7, or 1x10\^8 pfu.
OTHERPlacebo
0.9% Saline
Sponsors
BioProtection Systems Corporation
Department of Health and Human Services
Merck Sharp & Dohme LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Intervention model description
The study comprised two separate cohorts. Cohort 1 consisted of the 4 lower V920 dose groups (3x10\^3 pfu, 3x10\^4 pfu, 3x10\^5 pfu, and 3x10\^6 pfu). Cohort 2 consisted of the 3 higher V920 dose groups (9x10\^6 pfu, 2x10\^7 pfu, 1x10\^8 pfu) plus a bridging group that received vaccine at the highest dose evaluated in Cohort 1 (i.e. 3x10\^6 pfu). Both Cohorts 1 and 2 had a placebo group.
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy adult male or non-pregnant, non-lactating adult female, ages 18 to 60 (inclusive) at the time of screening 2. Have provided written informed consent prior to screening procedures 3. Free of clinically significant health problems, as determined by pertinent medical history, physical examination and clinical judgment of the investigator. 4. Available, able, and willing to participate for all study visits and procedures. 5. Males and females who are willing to practice abstinence from sexual intercourse with the opposite sex, or willing to use effective methods of contraception, from at least 30 days prior to vaccination until study end. 6. Be willing to minimize blood and body fluid exposure of others for 7 days after vaccination by: 1. Using effective barrier prophylaxis, such as latex condoms, during penetrative sexual intercourse 2. Avoiding the sharing of needles, razors, or toothbrushes 3. Avoiding open-mouth kissing 7. Resides in the geographic area of a clinical study site for 1 year after vaccination without risk of deployment outside the U.S.
Exclusion criteria
1. History of prior infection with a filovirus or prior participation in a filovirus vaccine trial 2. History of prior infection with VSV or receipt of a VSV vectored vaccine 3. Has been involved in the care in any capacity of a patient with Ebola virus infection within the previous 21 days 4. Is a healthcare worker who has direct contact with patients (nurse, physician, dentist, emergency medical technician, dental hygienist) 5. Has a house-hold contact (HHC) who is immunodeficient, on immunosuppressive medications, human immunodeficiency virus (HIV)-positive, pregnant, has an unstable medical condition 6. Has an HHC, or is a childcare worker who has direct contact with children, 5 years of age or younger 7. Direct hands-on job preparing food in the food industry 8. History of employment in an industry involved in contact with ruminant animals, veterinary sciences, or other potential exposure to VSV 9. History of employment or activity which involves potential contact with filoviruses 10. History of severe local or systemic reactions to any vaccination or a history of severe allergic reactions 11. Known allergy to the components of the BPSC1001 vaccine product 12. Receipt of investigational product up to 30 days prior to randomization or ongoing participation in another clinical trial 13. Receipt of licensed non-live vaccines within 14 days of planned study immunization (30 days for live vaccines) 14. Ability to observe possible local reactions at the eligible injections sites (deltoid region) is, in the opinion of the investigator, unacceptably obscured due to a physical condition or permanent body art 15. Acute or chronic, clinically significant psychiatric, hematologic, pulmonary, cardiovascular, or hepatic or renal functional abnormality as determined by the investigator based on medical history, physical examination, and/or laboratory screening test. This would include a known hemoglobinopathy or coagulation abnormality. 16. Any baseline laboratory screening test which in the opinion of the investigator, is considered clinically significant 17. Any serologic evidence of hepatitis B or C infection 18. Any confirmed or suspected immunosuppressive or immunodeficient condition, including HIV-1, HIV-2 infection, cytotoxic therapy in the previous 5 years, and/or diabetes 19. Any chronic or active neurologic disorder, including migraines, seizures, and epilepsy, excluding a single febrile seizure as a child 20. Have a known history of Guillain-Barré Syndrome 21. Have an active malignancy or history of metastatic or hematologic malignancy 22. Suspected or known alcohol and/or illicit drug abuse within the past 5 years 23. Moderate or severe illness and/or fever \>100.4°F within 1 week prior to vaccination (can be rescheduled) 24. Pregnant or lactating female, or female who intends to become pregnant during the study period 25. Administration of IgGs and/or any blood products within the 120 days preceding study entry or planned administration during the study period 26. History of blood donation within 60 days of enrollment or plans to donate within the study period 27. Administration of chronic (defined as more than 14 days) immunosuppressants or other immune modifying drugs within 6 months of study entry 1. For corticosteroids, this includes prednisone, or equivalent, greater than or equal to 0.5 mg/kg/day 2. Intranasal, topical, and intra-articular steroids are allowed 28. Unwilling to allow storage and use of blood for future vaccine research 28\. Research staff or the immediate family of research staff directly involved with the clinical study. 29\. Unwilling to undergo diagnostic evaluation of joint signs and symptoms, which may include arthrocentesis if clinically indicated based on presence of effusion and if the procedure is acceptable to the subject at the time (Cohort 2 only) 30. Unwilling to undergo diagnostic evaluation of skin rash, to include punch biopsy if clinically indicated and if the procedure is acceptable to the subject at the time (Cohort 2 only) 31. Research staff or the immediate family of research staff directly involved in the clinical study 32. Any other significant finding that in the opinion of the investigator would increase the risk of the individual having an adverse outcome from participating in this study 33. Elective surgery or hospitalization planned during the period of study participation 34. Has traveled to an area where the World Health Organization has declared as an Ebola outbreak zone 35. History of chronic inflammatory disease (e.g., rheumatoid arthritis, psoriatic arthritis, reactive arthritis, ankylosing spondylitis, systemic lupus erythematosus, psoriasis, Crohn's disease, ulcerative colitis, and gout), symptomatic osteoarthritis, or any other autoimmune or autoinflammatory disorder
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Optimum Dose for General Use Prophylaxis With V920 | Day 360 | The optimum dose for general use prophylaxis with V920 was determined following the review of all immunogenicity and safety data. |
| Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity | Up to 56 days postvaccination | An AE can be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. Unsolicited vaccine-related AEs were those events not specifically listed as either an injection-site (local) or systemic in the VRC and were reported as at least possibly related to the study vaccine or placebo. The AEs were further assessed for severity by the investigator as follows: Grade 1=Mild; Grade 2=Moderate; Grade 3=Severe; Grade 4=Potentially life-threatening. The percentage of participants that experienced at least one unsolicited vaccine-related AE was summarized by grade.. |
| Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | Up to 360 days postvaccination | An adverse event is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with study vaccine. An SAE is an AE that results in death, is life-threatening, results in a persistent or significant disability or incapacity, results in or prolongs an existing hospitalization, is a congenital anomaly or birth defect, or is another important medical event. SAEs were assessed for severity by the investigator as follows: Grade 1=Mild; Grade 2=Moderate; Grade 3=Severe; Grade 4=Potentially life-threatening; 5=Fatal. The percentage of participants that experienced at least 1 SAE was summarized by grade. |
| Geometric Mean Titers (GMTs) of Zaire Ebola Virus- (ZEBOV)-Specific Immunoglobulin-G (IgG) Antibody | 28 days postvaccination | Blood was drawn on Day 28 to assess the GMTs of ZEBOV-specific IgG antibodies as determined by Enzyme-linked immunosorbent assay (ELISA). |
| Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity | Up to 14 days postvaccination | An AE can be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. Injection-site AEs prompted on the Vaccination Report Card (VRC) were erythema, pain, tenderness and swelling. AEs were assessed for severity by the investigator according to a toxicity grading scale based on the FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. Grade 1=Mild; Grade 2=Moderate; Grade 3=Severe; Grade 4=Potentially life-threatening. The percentage of participants that experienced at least 1 solicited injection-site AE was summarized by grade. |
| Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity | Up to 14 days postvaccination | An AE can be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. Systemic AEs included subjective and objective fever, shivering/chills, sweats, myalgia, arthralgia, joint swelling, joint tenderness, fatigue, headache, gastrointestinal symptoms (nausea, vomiting, abdominal pain, and diarrhea), mucosal lesion, and skin lesion (including any blisters). AEs were assessed for severity by the investigator as follows: Grade 1=Mild; Grade 2=Moderate; Grade 3=Severe; Grade 4=Potentially life-threatening. The percentage of participants that experienced at least one systemic AE was summarized by grade. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Seroconversion for ZEBOV-specific IgG | 7, 14, 28, 56, 84 (Cohort 1 only), 180, and 360 days postvaccination | Blood was drawn on Days 7, 14, 28, 56, 84 (Cohort 1 only), 180, and 360 days to assess the GMTs via ELISA. Seroconversion was defined as a post-vaccination titer ≥ 200 ELISA Units/mL that was also at least a 4-fold increase in titer compared to baseline. |
| Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | 7, 14, 28, 56, 84 (Cohort 1 only), 180, and 360 days postvaccination | Blood was drawn on Days 7, 14, 28, 56, 84 (Cohort 1 only), 180, and 360 days to assess the GMTs of Zaire ebolavirus neutralizing antibodies as determined plaque reduction neutralization titer (reciprocal of the dilution that resulted in a 60% decrease in plaques) (PRNT60). |
| Mean Copies of Vector Ribonucleic Acid (RNA) for Participants With a V920 Polymerase Chain Reaction (PCR) Result ≥ Lower Limit of Quantification (LLOQ) | Days 1, 2, 3, 4, 7, 14 and 28 post-vaccination | Participants had blood, assessed for evidence of V920 via polymerase chain reaction (PCR). Mean copies of RNA was reported for all participants who had reading ≥ the LLOQ (62.5 copies/mL) |
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| 3x10^3 Pfu V920: Cohort 1 Participants received a single 1.0 mL intramuscular injection of V920 3x10\^3 pfu in the deltoid on Day 0 | 64 |
| 3x10^4 Pfu V920: Cohort 1 Participants received a 1.0 mL intramuscular injection of V920 3x10\^4 pfu in the deltoid on Day 0. | 64 |
| 3x10^5 Pfu V920: Cohort 1 Participants received a 1.0 mL intramuscular injection of V920 3x10\^5 pfu in the deltoid on Day 0. | 64 |
| 3x10^6 Pfu V920: Cohort 1 Participants received a 1.0 mL intramuscular injection of V920 3x10\^6 pfu in the deltoid on Day 0. | 64 |
| Placebo Cohort 1 Participants received a single 1.0 mL intramuscular injection of placebo in the deltoid on Day 0. | 74 |
| 3x10^6 Pfu V920: Cohort 2 Participants received a single 1.0 mL intramuscular injection of V920 3x10\^6 pfu in the deltoid on Day 0 | 20 |
| 9x10^6 Pfu V920: Cohort 2 Participants received a 1.0 mL intramuscular injection of V920 9x10\^6 pfu in the deltoid on Day 0. | 47 |
| 2x10^7 Pfu V920: Cohort 2 Participants received a 1.0 mL intramuscular injection of V920 2x10\^7 pfu in the deltoid on Day 0. | 47 |
| 1x10^8 Pfu V920: Cohort 2 Participants received a 1.0 mL intramuscular injection of V920 1x10\^8 pfu in the deltoid on Day 0. | 48 |
| Placebo: Cohort 2 Participants received a single 1.0 mL intramuscular injection of placebo in the deltoid on Day 0 | 20 |
| Total | 512 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 | FG008 | FG009 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study | Death | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Overall Study | Lost to Follow-up | 2 | 3 | 1 | 0 | 0 | 0 | 3 | 4 | 2 | 0 |
| Overall Study | Participant relocation | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Overall Study | Participant unavailable | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Overall Study | Physician Decision | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Overall Study | Screen failure | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Overall Study | Withdrawal by Subject | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
Baseline characteristics
| Characteristic | 3x10^3 Pfu V920: Cohort 1 | 3x10^4 Pfu V920: Cohort 1 | 3x10^5 Pfu V920: Cohort 1 | 3x10^6 Pfu V920: Cohort 1 | Placebo Cohort 1 | 3x10^6 Pfu V920: Cohort 2 | 9x10^6 Pfu V920: Cohort 2 | 2x10^7 Pfu V920: Cohort 2 | 1x10^8 Pfu V920: Cohort 2 | Placebo: Cohort 2 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 64 Participants | 64 Participants | 64 Participants | 64 Participants | 74 Participants | 20 Participants | 47 Participants | 47 Participants | 48 Participants | 20 Participants | 512 Participants |
| Sex: Female, Male Female | 32 Participants | 33 Participants | 31 Participants | 33 Participants | 39 Participants | 8 Participants | 24 Participants | 22 Participants | 15 Participants | 8 Participants | 245 Participants |
| Sex: Female, Male Male | 32 Participants | 31 Participants | 33 Participants | 31 Participants | 35 Participants | 12 Participants | 23 Participants | 25 Participants | 33 Participants | 12 Participants | 267 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk | EG009 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 64 | 0 / 64 | 0 / 64 | 1 / 64 | 0 / 74 | 0 / 20 | 0 / 47 | 0 / 47 | 0 / 48 | 0 / 20 |
| other Total, other adverse events | 30 / 64 | 38 / 64 | 44 / 64 | 52 / 64 | 43 / 74 | 14 / 20 | 43 / 47 | 41 / 47 | 41 / 48 | 9 / 20 |
| serious Total, serious adverse events | 0 / 64 | 0 / 64 | 1 / 64 | 2 / 64 | 1 / 74 | 0 / 20 | 0 / 47 | 0 / 47 | 0 / 48 | 0 / 20 |
Outcome results
Primary
Geometric Mean Titers (GMTs) of Zaire Ebola Virus- (ZEBOV)-Specific Immunoglobulin-G (IgG) Antibody
Blood was drawn on Day 28 to assess the GMTs of ZEBOV-specific IgG antibodies as determined by Enzyme-linked immunosorbent assay (ELISA).
Time frame: 28 days postvaccination
Population: All participants who were vaccinated, had endpoint titer results on Days 0 (baseline) and 28 (relative Days 24-35), and who did not have any protocol violations that influenced interpretation of immunogenicity endpoints. A subset of 25 placebo recipients in Cohort 1 were prospectively identified for testing of immunogenicity endpoints.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| 3x10^3 Pfu V920: Cohort 1 | Geometric Mean Titers (GMTs) of Zaire Ebola Virus- (ZEBOV)-Specific Immunoglobulin-G (IgG) Antibody | 777.8 ELISA Units/mL | Standard Deviation 5.06 |
| 3x10^4 Pfu V920: Cohort 1 | Geometric Mean Titers (GMTs) of Zaire Ebola Virus- (ZEBOV)-Specific Immunoglobulin-G (IgG) Antibody | 767.8 ELISA Units/mL | Standard Deviation 3.96 |
| 3x10^5 Pfu V920: Cohort 1 | Geometric Mean Titers (GMTs) of Zaire Ebola Virus- (ZEBOV)-Specific Immunoglobulin-G (IgG) Antibody | 909.6 ELISA Units/mL | Standard Deviation 3.26 |
| 3x10^6 Pfu V920: Cohort 1 | Geometric Mean Titers (GMTs) of Zaire Ebola Virus- (ZEBOV)-Specific Immunoglobulin-G (IgG) Antibody | 1139.9 ELISA Units/mL | Standard Deviation 3.25 |
| Placebo: Cohort 1 | Geometric Mean Titers (GMTs) of Zaire Ebola Virus- (ZEBOV)-Specific Immunoglobulin-G (IgG) Antibody | 30.3 ELISA Units/mL | Standard Deviation 1 |
| 3x10^6 Pfu V920: Cohort 2 | Geometric Mean Titers (GMTs) of Zaire Ebola Virus- (ZEBOV)-Specific Immunoglobulin-G (IgG) Antibody | 1518.9 ELISA Units/mL | Standard Deviation 3.2 |
| 9x10^6 Pfu V920: Cohort 2 | Geometric Mean Titers (GMTs) of Zaire Ebola Virus- (ZEBOV)-Specific Immunoglobulin-G (IgG) Antibody | 977.4 ELISA Units/mL | Standard Deviation 3.01 |
| 2x10^7 Pfu V920: Cohort 2 | Geometric Mean Titers (GMTs) of Zaire Ebola Virus- (ZEBOV)-Specific Immunoglobulin-G (IgG) Antibody | 1542.8 ELISA Units/mL | Standard Deviation 3.1 |
| 1x10^8 Pfu V920: Cohort 2 | Geometric Mean Titers (GMTs) of Zaire Ebola Virus- (ZEBOV)-Specific Immunoglobulin-G (IgG) Antibody | 1930.3 ELISA Units/mL | Standard Deviation 2.22 |
| Placebo: Cohort 2 | Geometric Mean Titers (GMTs) of Zaire Ebola Virus- (ZEBOV)-Specific Immunoglobulin-G (IgG) Antibody | 35.9 ELISA Units/mL | Standard Deviation 2.13 |
p-value: <0.001ANOVA
p-value: 0.37ANOVA
p-value: <0.001ANOVA
p-value: 0.068ANOVA
p-value: 0.007ANOVA
p-value: 0.951ANOVA
p-value: 0.458ANOVA
p-value: 0.071ANOVA
p-value: <0.001ANOVA
p-value: 0.029ANOVA
p-value: 0.325ANOVA
p-value: 0.003ANOVA
p-value: <0.001ANOVA
p-value: 0.427ANOVA
p-value: 0.065ANOVA
p-value: <0.001ANOVA
p-value: 0.027ANOVA
p-value: 0.303ANOVA
p-value: 0.003ANOVA
p-value: <0.001ANOVA
p-value: 0.286ANOVA
p-value: <0.001ANOVA
p-value: 0.094ANOVA
p-value: 0.757ANOVA
p-value: 0.022ANOVA
p-value: 0.001ANOVA
p-value: <0.001ANOVA
p-value: 0.348ANOVA
p-value: 0.508ANOVA
p-value: 0.191ANOVA
p-value: 0.024ANOVA
p-value: 0.169ANOVA
p-value: 0.961ANOVA
p-value: 0.454ANOVA
p-value: <0.001ANOVA
Primary
Optimum Dose for General Use Prophylaxis With V920
The optimum dose for general use prophylaxis with V920 was determined following the review of all immunogenicity and safety data.
Time frame: Day 360
Population: All participants who received study vaccine
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 3x10^3 Pfu V920: Cohort 1 | Optimum Dose for General Use Prophylaxis With V920 | 20000000 pfu |
Primary
Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity
An adverse event is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with study vaccine. An SAE is an AE that results in death, is life-threatening, results in a persistent or significant disability or incapacity, results in or prolongs an existing hospitalization, is a congenital anomaly or birth defect, or is another important medical event. SAEs were assessed for severity by the investigator as follows: Grade 1=Mild; Grade 2=Moderate; Grade 3=Severe; Grade 4=Potentially life-threatening; 5=Fatal. The percentage of participants that experienced at least 1 SAE was summarized by grade.
Time frame: Up to 360 days postvaccination
Population: All randomized participants who received study vaccination and had data available for the endpoint.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| 3x10^3 Pfu V920: Cohort 1 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 5 (Fatal) | 0 Percentage of Participants |
| 3x10^3 Pfu V920: Cohort 1 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 3 (Severe) | 0 Percentage of Participants |
| 3x10^3 Pfu V920: Cohort 1 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 4 (Potentially Life-threatening) | 0 Percentage of Participants |
| 3x10^3 Pfu V920: Cohort 1 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 2 (Moderate) | 0 Percentage of Participants |
| 3x10^3 Pfu V920: Cohort 1 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 1 (Mild) | 0 Percentage of Participants |
| 3x10^4 Pfu V920: Cohort 1 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 1 (Mild) | 0 Percentage of Participants |
| 3x10^4 Pfu V920: Cohort 1 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 4 (Potentially Life-threatening) | 0 Percentage of Participants |
| 3x10^4 Pfu V920: Cohort 1 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 2 (Moderate) | 0 Percentage of Participants |
| 3x10^4 Pfu V920: Cohort 1 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 3 (Severe) | 0 Percentage of Participants |
| 3x10^4 Pfu V920: Cohort 1 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 5 (Fatal) | 0 Percentage of Participants |
| 3x10^5 Pfu V920: Cohort 1 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 3 (Severe) | 0 Percentage of Participants |
| 3x10^5 Pfu V920: Cohort 1 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 2 (Moderate) | 0 Percentage of Participants |
| 3x10^5 Pfu V920: Cohort 1 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 1 (Mild) | 0 Percentage of Participants |
| 3x10^5 Pfu V920: Cohort 1 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 4 (Potentially Life-threatening) | 1.6 Percentage of Participants |
| 3x10^5 Pfu V920: Cohort 1 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 5 (Fatal) | 0 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 1 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 4 (Potentially Life-threatening) | 0 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 1 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 1 (Mild) | 1.6 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 1 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 3 (Severe) | 0 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 1 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 2 (Moderate) | 0 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 1 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 5 (Fatal) | 1.6 Percentage of Participants |
| Placebo: Cohort 1 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 5 (Fatal) | 0 Percentage of Participants |
| Placebo: Cohort 1 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 3 (Severe) | 1.4 Percentage of Participants |
| Placebo: Cohort 1 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 4 (Potentially Life-threatening) | 0 Percentage of Participants |
| Placebo: Cohort 1 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 1 (Mild) | 0 Percentage of Participants |
| Placebo: Cohort 1 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 2 (Moderate) | 0 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 2 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 2 (Moderate) | 0 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 2 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 4 (Potentially Life-threatening) | 0 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 2 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 3 (Severe) | 0 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 2 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 5 (Fatal) | 0 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 2 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 1 (Mild) | 0 Percentage of Participants |
| 9x10^6 Pfu V920: Cohort 2 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 5 (Fatal) | 0 Percentage of Participants |
| 9x10^6 Pfu V920: Cohort 2 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 4 (Potentially Life-threatening) | 0 Percentage of Participants |
| 9x10^6 Pfu V920: Cohort 2 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 2 (Moderate) | 0 Percentage of Participants |
| 9x10^6 Pfu V920: Cohort 2 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 3 (Severe) | 0 Percentage of Participants |
| 9x10^6 Pfu V920: Cohort 2 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 1 (Mild) | 0 Percentage of Participants |
| 2x10^7 Pfu V920: Cohort 2 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 4 (Potentially Life-threatening) | 0 Percentage of Participants |
| 2x10^7 Pfu V920: Cohort 2 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 1 (Mild) | 0 Percentage of Participants |
| 2x10^7 Pfu V920: Cohort 2 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 5 (Fatal) | 0 Percentage of Participants |
| 2x10^7 Pfu V920: Cohort 2 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 3 (Severe) | 0 Percentage of Participants |
| 2x10^7 Pfu V920: Cohort 2 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 2 (Moderate) | 0 Percentage of Participants |
| 1x10^8 Pfu V920: Cohort 2 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 5 (Fatal) | 0 Percentage of Participants |
| 1x10^8 Pfu V920: Cohort 2 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 1 (Mild) | 0 Percentage of Participants |
| 1x10^8 Pfu V920: Cohort 2 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 4 (Potentially Life-threatening) | 0 Percentage of Participants |
| 1x10^8 Pfu V920: Cohort 2 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 3 (Severe) | 0 Percentage of Participants |
| 1x10^8 Pfu V920: Cohort 2 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 2 (Moderate) | 0 Percentage of Participants |
| Placebo: Cohort 2 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 1 (Mild) | 0 Percentage of Participants |
| Placebo: Cohort 2 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 5 (Fatal) | 0 Percentage of Participants |
| Placebo: Cohort 2 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 2 (Moderate) | 0 Percentage of Participants |
| Placebo: Cohort 2 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 4 (Potentially Life-threatening) | 0 Percentage of Participants |
| Placebo: Cohort 2 | Percentage of Participants With One or More Serious Adverse Event (SAE) by Severity | 3 (Severe) | 0 Percentage of Participants |
Primary
Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity
An AE can be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. Injection-site AEs prompted on the Vaccination Report Card (VRC) were erythema, pain, tenderness and swelling. AEs were assessed for severity by the investigator according to a toxicity grading scale based on the FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. Grade 1=Mild; Grade 2=Moderate; Grade 3=Severe; Grade 4=Potentially life-threatening. The percentage of participants that experienced at least 1 solicited injection-site AE was summarized by grade.
Time frame: Up to 14 days postvaccination
Population: All randomized participants who received study vaccination and had data available for the endpoint.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| 3x10^3 Pfu V920: Cohort 1 | Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity | Grade 4 (Potentially life-threatening) | 0 Percentage of Participants |
| 3x10^3 Pfu V920: Cohort 1 | Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity | Grade 2 (Moderate) | 0 Percentage of Participants |
| 3x10^3 Pfu V920: Cohort 1 | Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity | Grade 3 (Severe) | 0 Percentage of Participants |
| 3x10^3 Pfu V920: Cohort 1 | Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity | Grade 1 (Mild) | 17.2 Percentage of Participants |
| 3x10^4 Pfu V920: Cohort 1 | Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity | Grade 4 (Potentially life-threatening) | 0 Percentage of Participants |
| 3x10^4 Pfu V920: Cohort 1 | Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity | Grade 3 (Severe) | 0 Percentage of Participants |
| 3x10^4 Pfu V920: Cohort 1 | Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity | Grade 1 (Mild) | 21.9 Percentage of Participants |
| 3x10^4 Pfu V920: Cohort 1 | Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity | Grade 2 (Moderate) | 1.6 Percentage of Participants |
| 3x10^5 Pfu V920: Cohort 1 | Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity | Grade 3 (Severe) | 0 Percentage of Participants |
| 3x10^5 Pfu V920: Cohort 1 | Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity | Grade 2 (Moderate) | 1.6 Percentage of Participants |
| 3x10^5 Pfu V920: Cohort 1 | Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity | Grade 1 (Mild) | 29.7 Percentage of Participants |
| 3x10^5 Pfu V920: Cohort 1 | Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity | Grade 4 (Potentially life-threatening) | 0 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 1 | Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity | Grade 4 (Potentially life-threatening) | 0 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 1 | Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity | Grade 1 (Mild) | 45.3 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 1 | Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity | Grade 2 (Moderate) | 1.6 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 1 | Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity | Grade 3 (Severe) | 0 Percentage of Participants |
| Placebo: Cohort 1 | Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity | Grade 1 (Mild) | 10.8 Percentage of Participants |
| Placebo: Cohort 1 | Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity | Grade 3 (Severe) | 0 Percentage of Participants |
| Placebo: Cohort 1 | Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity | Grade 4 (Potentially life-threatening) | 0 Percentage of Participants |
| Placebo: Cohort 1 | Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity | Grade 2 (Moderate) | 1.4 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 2 | Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity | Grade 1 (Mild) | 30.0 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 2 | Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity | Grade 2 (Moderate) | 0 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 2 | Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity | Grade 3 (Severe) | 0 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 2 | Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity | Grade 4 (Potentially life-threatening) | 0 Percentage of Participants |
| 9x10^6 Pfu V920: Cohort 2 | Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity | Grade 3 (Severe) | 0 Percentage of Participants |
| 9x10^6 Pfu V920: Cohort 2 | Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity | Grade 1 (Mild) | 61.7 Percentage of Participants |
| 9x10^6 Pfu V920: Cohort 2 | Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity | Grade 2 (Moderate) | 8.5 Percentage of Participants |
| 9x10^6 Pfu V920: Cohort 2 | Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity | Grade 4 (Potentially life-threatening) | 0 Percentage of Participants |
| 2x10^7 Pfu V920: Cohort 2 | Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity | Grade 4 (Potentially life-threatening) | 0 Percentage of Participants |
| 2x10^7 Pfu V920: Cohort 2 | Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity | Grade 1 (Mild) | 63.8 Percentage of Participants |
| 2x10^7 Pfu V920: Cohort 2 | Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity | Grade 2 (Moderate) | 8.5 Percentage of Participants |
| 2x10^7 Pfu V920: Cohort 2 | Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity | Grade 3 (Severe) | 0 Percentage of Participants |
| 1x10^8 Pfu V920: Cohort 2 | Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity | Grade 2 (Moderate) | 16.7 Percentage of Participants |
| 1x10^8 Pfu V920: Cohort 2 | Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity | Grade 4 (Potentially life-threatening) | 0 Percentage of Participants |
| 1x10^8 Pfu V920: Cohort 2 | Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity | Grade 3 (Severe) | 0 Percentage of Participants |
| 1x10^8 Pfu V920: Cohort 2 | Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity | Grade 1 (Mild) | 47.9 Percentage of Participants |
| Placebo: Cohort 2 | Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity | Grade 4 (Potentially life-threatening) | 0 Percentage of Participants |
| Placebo: Cohort 2 | Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity | Grade 1 (Mild) | 5.0 Percentage of Participants |
| Placebo: Cohort 2 | Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity | Grade 2 (Moderate) | 0 Percentage of Participants |
| Placebo: Cohort 2 | Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity | Grade 3 (Severe) | 0 Percentage of Participants |
Primary
Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity
An AE can be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. Systemic AEs included subjective and objective fever, shivering/chills, sweats, myalgia, arthralgia, joint swelling, joint tenderness, fatigue, headache, gastrointestinal symptoms (nausea, vomiting, abdominal pain, and diarrhea), mucosal lesion, and skin lesion (including any blisters). AEs were assessed for severity by the investigator as follows: Grade 1=Mild; Grade 2=Moderate; Grade 3=Severe; Grade 4=Potentially life-threatening. The percentage of participants that experienced at least one systemic AE was summarized by grade.
Time frame: Up to 14 days postvaccination
Population: All randomized participants who received study vaccination and had data available for the endpoint.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| 3x10^3 Pfu V920: Cohort 1 | Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity | Grade 2 (Moderate) | 10.9 Percentage of Participants |
| 3x10^3 Pfu V920: Cohort 1 | Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity | Grade 3 (Severe) | 0 Percentage of Participants |
| 3x10^3 Pfu V920: Cohort 1 | Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity | Grade 4 (Potentially life-threatening) | 0 Percentage of Participants |
| 3x10^3 Pfu V920: Cohort 1 | Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity | Grade 1 (Mild) | 29.7 Percentage of Participants |
| 3x10^4 Pfu V920: Cohort 1 | Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity | Grade 4 (Potentially life-threatening) | 0 Percentage of Participants |
| 3x10^4 Pfu V920: Cohort 1 | Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity | Grade 1 (Mild) | 39.1 Percentage of Participants |
| 3x10^4 Pfu V920: Cohort 1 | Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity | Grade 3 (Severe) | 0 Percentage of Participants |
| 3x10^4 Pfu V920: Cohort 1 | Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity | Grade 2 (Moderate) | 4.7 Percentage of Participants |
| 3x10^5 Pfu V920: Cohort 1 | Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity | Grade 3 (Severe) | 3.1 Percentage of Participants |
| 3x10^5 Pfu V920: Cohort 1 | Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity | Grade 1 (Mild) | 45.3 Percentage of Participants |
| 3x10^5 Pfu V920: Cohort 1 | Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity | Grade 4 (Potentially life-threatening) | 0 Percentage of Participants |
| 3x10^5 Pfu V920: Cohort 1 | Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity | Grade 2 (Moderate) | 10.9 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 1 | Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity | Grade 4 (Potentially life-threatening) | 0 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 1 | Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity | Grade 2 (Moderate) | 14.1 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 1 | Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity | Grade 3 (Severe) | 1.6 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 1 | Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity | Grade 1 (Mild) | 53.1 Percentage of Participants |
| Placebo: Cohort 1 | Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity | Grade 1 (Mild) | 41.9 Percentage of Participants |
| Placebo: Cohort 1 | Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity | Grade 3 (Severe) | 0 Percentage of Participants |
| Placebo: Cohort 1 | Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity | Grade 2 (Moderate) | 4.1 Percentage of Participants |
| Placebo: Cohort 1 | Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity | Grade 4 (Potentially life-threatening) | 0 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 2 | Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity | Grade 1 (Mild) | 25.0 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 2 | Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity | Grade 4 (Potentially life-threatening) | 0 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 2 | Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity | Grade 3 (Severe) | 0 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 2 | Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity | Grade 2 (Moderate) | 25.0 Percentage of Participants |
| 9x10^6 Pfu V920: Cohort 2 | Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity | Grade 4 (Potentially life-threatening) | 0 Percentage of Participants |
| 9x10^6 Pfu V920: Cohort 2 | Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity | Grade 1 (Mild) | 46.8 Percentage of Participants |
| 9x10^6 Pfu V920: Cohort 2 | Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity | Grade 2 (Moderate) | 19.1 Percentage of Participants |
| 9x10^6 Pfu V920: Cohort 2 | Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity | Grade 3 (Severe) | 2.1 Percentage of Participants |
| 2x10^7 Pfu V920: Cohort 2 | Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity | Grade 3 (Severe) | 4.3 Percentage of Participants |
| 2x10^7 Pfu V920: Cohort 2 | Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity | Grade 1 (Mild) | 46.8 Percentage of Participants |
| 2x10^7 Pfu V920: Cohort 2 | Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity | Grade 2 (Moderate) | 23.4 Percentage of Participants |
| 2x10^7 Pfu V920: Cohort 2 | Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity | Grade 4 (Potentially life-threatening) | 0 Percentage of Participants |
| 1x10^8 Pfu V920: Cohort 2 | Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity | Grade 1 (Mild) | 43.8 Percentage of Participants |
| 1x10^8 Pfu V920: Cohort 2 | Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity | Grade 2 (Moderate) | 27.1 Percentage of Participants |
| 1x10^8 Pfu V920: Cohort 2 | Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity | Grade 3 (Severe) | 4.2 Percentage of Participants |
| 1x10^8 Pfu V920: Cohort 2 | Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity | Grade 4 (Potentially life-threatening) | 0 Percentage of Participants |
| Placebo: Cohort 2 | Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity | Grade 4 (Potentially life-threatening) | 0 Percentage of Participants |
| Placebo: Cohort 2 | Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity | Grade 1 (Mild) | 20.0 Percentage of Participants |
| Placebo: Cohort 2 | Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity | Grade 2 (Moderate) | 5.0 Percentage of Participants |
| Placebo: Cohort 2 | Percentage of Participants With One or More Solicited Systemic Adverse Events by Severity | Grade 3 (Severe) | 0 Percentage of Participants |
Primary
Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity
An AE can be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. Unsolicited vaccine-related AEs were those events not specifically listed as either an injection-site (local) or systemic in the VRC and were reported as at least possibly related to the study vaccine or placebo. The AEs were further assessed for severity by the investigator as follows: Grade 1=Mild; Grade 2=Moderate; Grade 3=Severe; Grade 4=Potentially life-threatening. The percentage of participants that experienced at least one unsolicited vaccine-related AE was summarized by grade..
Time frame: Up to 56 days postvaccination
Population: All randomized participants who received study vaccination and had data available for the endpoint.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| 3x10^3 Pfu V920: Cohort 1 | Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity | 2 (Moderate) | 4.7 Percentage of Participants |
| 3x10^3 Pfu V920: Cohort 1 | Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity | 1 (Mild) | 7.8 Percentage of Participants |
| 3x10^3 Pfu V920: Cohort 1 | Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity | 4 (Potentially Life-threatening) | 0 Percentage of Participants |
| 3x10^3 Pfu V920: Cohort 1 | Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity | 3 (Severe) | 0 Percentage of Participants |
| 3x10^4 Pfu V920: Cohort 1 | Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity | 4 (Potentially Life-threatening) | 0 Percentage of Participants |
| 3x10^4 Pfu V920: Cohort 1 | Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity | 1 (Mild) | 14.1 Percentage of Participants |
| 3x10^4 Pfu V920: Cohort 1 | Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity | 3 (Severe) | 0 Percentage of Participants |
| 3x10^4 Pfu V920: Cohort 1 | Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity | 2 (Moderate) | 3.1 Percentage of Participants |
| 3x10^5 Pfu V920: Cohort 1 | Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity | 3 (Severe) | 0 Percentage of Participants |
| 3x10^5 Pfu V920: Cohort 1 | Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity | 1 (Mild) | 7.8 Percentage of Participants |
| 3x10^5 Pfu V920: Cohort 1 | Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity | 4 (Potentially Life-threatening) | 0 Percentage of Participants |
| 3x10^5 Pfu V920: Cohort 1 | Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity | 2 (Moderate) | 0 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 1 | Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity | 4 (Potentially Life-threatening) | 0 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 1 | Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity | 1 (Mild) | 9.4 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 1 | Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity | 2 (Moderate) | 3.1 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 1 | Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity | 3 (Severe) | 1.6 Percentage of Participants |
| Placebo: Cohort 1 | Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity | 4 (Potentially Life-threatening) | 0 Percentage of Participants |
| Placebo: Cohort 1 | Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity | 2 (Moderate) | 0 Percentage of Participants |
| Placebo: Cohort 1 | Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity | 1 (Mild) | 6.8 Percentage of Participants |
| Placebo: Cohort 1 | Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity | 3 (Severe) | 0 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 2 | Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity | 1 (Mild) | 15.0 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 2 | Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity | 3 (Severe) | 0 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 2 | Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity | 4 (Potentially Life-threatening) | 0 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 2 | Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity | 2 (Moderate) | 0 Percentage of Participants |
| 9x10^6 Pfu V920: Cohort 2 | Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity | 4 (Potentially Life-threatening) | 0 Percentage of Participants |
| 9x10^6 Pfu V920: Cohort 2 | Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity | 1 (Mild) | 14.9 Percentage of Participants |
| 9x10^6 Pfu V920: Cohort 2 | Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity | 3 (Severe) | 0 Percentage of Participants |
| 9x10^6 Pfu V920: Cohort 2 | Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity | 2 (Moderate) | 6.4 Percentage of Participants |
| 2x10^7 Pfu V920: Cohort 2 | Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity | 3 (Severe) | 0 Percentage of Participants |
| 2x10^7 Pfu V920: Cohort 2 | Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity | 1 (Mild) | 17.0 Percentage of Participants |
| 2x10^7 Pfu V920: Cohort 2 | Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity | 2 (Moderate) | 2.1 Percentage of Participants |
| 2x10^7 Pfu V920: Cohort 2 | Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity | 4 (Potentially Life-threatening) | 0 Percentage of Participants |
| 1x10^8 Pfu V920: Cohort 2 | Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity | 1 (Mild) | 14.6 Percentage of Participants |
| 1x10^8 Pfu V920: Cohort 2 | Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity | 2 (Moderate) | 2.1 Percentage of Participants |
| 1x10^8 Pfu V920: Cohort 2 | Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity | 3 (Severe) | 0 Percentage of Participants |
| 1x10^8 Pfu V920: Cohort 2 | Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity | 4 (Potentially Life-threatening) | 0 Percentage of Participants |
| Placebo: Cohort 2 | Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity | 4 (Potentially Life-threatening) | 0 Percentage of Participants |
| Placebo: Cohort 2 | Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity | 1 (Mild) | 10.0 Percentage of Participants |
| Placebo: Cohort 2 | Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity | 2 (Moderate) | 0 Percentage of Participants |
| Placebo: Cohort 2 | Percentage of Participants With One or More Unsolicited Vaccine-related Adverse Event by Severity | 3 (Severe) | 5.0 Percentage of Participants |
Secondary
Mean Copies of Vector Ribonucleic Acid (RNA) for Participants With a V920 Polymerase Chain Reaction (PCR) Result ≥ Lower Limit of Quantification (LLOQ)
Participants had blood, assessed for evidence of V920 via polymerase chain reaction (PCR). Mean copies of RNA was reported for all participants who had reading ≥ the LLOQ (62.5 copies/mL)
Time frame: Days 1, 2, 3, 4, 7, 14 and 28 post-vaccination
Population: All participants who were vaccinated, had endpoint titer results on Days 0 (baseline) and 28 (relative Days 24-35), and who did not have any protocol violations that influenced interpretation of immunogenicity endpoints. A subset of 25 placebo recipients in Cohort 1 were prospectively identified for testing of immunogenicity endpoints.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| 3x10^3 Pfu V920: Cohort 1 | Mean Copies of Vector Ribonucleic Acid (RNA) for Participants With a V920 Polymerase Chain Reaction (PCR) Result ≥ Lower Limit of Quantification (LLOQ) | Day 4 | 23936.00 copies/mL | — |
| 3x10^3 Pfu V920: Cohort 1 | Mean Copies of Vector Ribonucleic Acid (RNA) for Participants With a V920 Polymerase Chain Reaction (PCR) Result ≥ Lower Limit of Quantification (LLOQ) | Day 2 | 4107.00 copies/mL | — |
| 3x10^3 Pfu V920: Cohort 1 | Mean Copies of Vector Ribonucleic Acid (RNA) for Participants With a V920 Polymerase Chain Reaction (PCR) Result ≥ Lower Limit of Quantification (LLOQ) | Day 7 | 787.00 copies/mL | — |
| 3x10^3 Pfu V920: Cohort 1 | Mean Copies of Vector Ribonucleic Acid (RNA) for Participants With a V920 Polymerase Chain Reaction (PCR) Result ≥ Lower Limit of Quantification (LLOQ) | Day 3 | 12649.00 copies/mL | — |
| 3x10^4 Pfu V920: Cohort 1 | Mean Copies of Vector Ribonucleic Acid (RNA) for Participants With a V920 Polymerase Chain Reaction (PCR) Result ≥ Lower Limit of Quantification (LLOQ) | Day 4 | 109.40 copies/mL | — |
| 3x10^4 Pfu V920: Cohort 1 | Mean Copies of Vector Ribonucleic Acid (RNA) for Participants With a V920 Polymerase Chain Reaction (PCR) Result ≥ Lower Limit of Quantification (LLOQ) | Day 3 | 109.40 copies/mL | — |
| 3x10^5 Pfu V920: Cohort 1 | Mean Copies of Vector Ribonucleic Acid (RNA) for Participants With a V920 Polymerase Chain Reaction (PCR) Result ≥ Lower Limit of Quantification (LLOQ) | Day 7 | 160.00 copies/mL | — |
| 3x10^6 Pfu V920: Cohort 1 | Mean Copies of Vector Ribonucleic Acid (RNA) for Participants With a V920 Polymerase Chain Reaction (PCR) Result ≥ Lower Limit of Quantification (LLOQ) | Day 1 | 118.04 copies/mL | Standard Deviation 1.185 |
| 3x10^6 Pfu V920: Cohort 1 | Mean Copies of Vector Ribonucleic Acid (RNA) for Participants With a V920 Polymerase Chain Reaction (PCR) Result ≥ Lower Limit of Quantification (LLOQ) | Day 2 | 127.13 copies/mL | Standard Deviation 1.511 |
| 3x10^6 Pfu V920: Cohort 1 | Mean Copies of Vector Ribonucleic Acid (RNA) for Participants With a V920 Polymerase Chain Reaction (PCR) Result ≥ Lower Limit of Quantification (LLOQ) | Day 3 | 703.36 copies/mL | Standard Deviation 25.106 |
| 3x10^6 Pfu V920: Cohort 1 | Mean Copies of Vector Ribonucleic Acid (RNA) for Participants With a V920 Polymerase Chain Reaction (PCR) Result ≥ Lower Limit of Quantification (LLOQ) | Day 14 | 109.40 copies/mL | — |
| 3x10^6 Pfu V920: Cohort 2 | Mean Copies of Vector Ribonucleic Acid (RNA) for Participants With a V920 Polymerase Chain Reaction (PCR) Result ≥ Lower Limit of Quantification (LLOQ) | Day 2 | 109.40 copies/mL | — |
| 3x10^6 Pfu V920: Cohort 2 | Mean Copies of Vector Ribonucleic Acid (RNA) for Participants With a V920 Polymerase Chain Reaction (PCR) Result ≥ Lower Limit of Quantification (LLOQ) | Day 1 | 109.40 copies/mL | — |
| 9x10^6 Pfu V920: Cohort 2 | Mean Copies of Vector Ribonucleic Acid (RNA) for Participants With a V920 Polymerase Chain Reaction (PCR) Result ≥ Lower Limit of Quantification (LLOQ) | Day 2 | 158.74 copies/mL | Standard Deviation 1.901 |
| 9x10^6 Pfu V920: Cohort 2 | Mean Copies of Vector Ribonucleic Acid (RNA) for Participants With a V920 Polymerase Chain Reaction (PCR) Result ≥ Lower Limit of Quantification (LLOQ) | Day 1 | 144.72 copies/mL | Standard Deviation 1.511 |
| 2x10^7 Pfu V920: Cohort 2 | Mean Copies of Vector Ribonucleic Acid (RNA) for Participants With a V920 Polymerase Chain Reaction (PCR) Result ≥ Lower Limit of Quantification (LLOQ) | Day 3 | 109.40 copies/mL | — |
| 2x10^7 Pfu V920: Cohort 2 | Mean Copies of Vector Ribonucleic Acid (RNA) for Participants With a V920 Polymerase Chain Reaction (PCR) Result ≥ Lower Limit of Quantification (LLOQ) | Day 2 | 172.24 copies/mL | Standard Deviation 1.628 |
| 2x10^7 Pfu V920: Cohort 2 | Mean Copies of Vector Ribonucleic Acid (RNA) for Participants With a V920 Polymerase Chain Reaction (PCR) Result ≥ Lower Limit of Quantification (LLOQ) | Day 1 | 184.65 copies/mL | Standard Deviation 1.893 |
| 1x10^8 Pfu V920: Cohort 2 | Mean Copies of Vector Ribonucleic Acid (RNA) for Participants With a V920 Polymerase Chain Reaction (PCR) Result ≥ Lower Limit of Quantification (LLOQ) | Day 2 | 161.67 copies/mL | Standard Deviation 1.644 |
| 1x10^8 Pfu V920: Cohort 2 | Mean Copies of Vector Ribonucleic Acid (RNA) for Participants With a V920 Polymerase Chain Reaction (PCR) Result ≥ Lower Limit of Quantification (LLOQ) | Day 3 | 740.96 copies/mL | Standard Deviation 8.199 |
| 1x10^8 Pfu V920: Cohort 2 | Mean Copies of Vector Ribonucleic Acid (RNA) for Participants With a V920 Polymerase Chain Reaction (PCR) Result ≥ Lower Limit of Quantification (LLOQ) | Day 1 | 304.45 copies/mL | Standard Deviation 2.534 |
Secondary
Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies
Blood was drawn on Days 7, 14, 28, 56, 84 (Cohort 1 only), 180, and 360 days to assess the GMTs of Zaire ebolavirus neutralizing antibodies as determined plaque reduction neutralization titer (reciprocal of the dilution that resulted in a 60% decrease in plaques) (PRNT60).
Time frame: 7, 14, 28, 56, 84 (Cohort 1 only), 180, and 360 days postvaccination
Population: All participants who were vaccinated, had endpoint titer results on Days 0 (baseline) and 28 (relative Days 24-35), and who did not have any protocol violations that influenced interpretation of immunogenicity endpoints. A subset of 25 placebo recipients in Cohort 1 were prospectively identified for testing of immunogenicity endpoints.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| 3x10^3 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 180 | 81.0 Percentage of Participants |
| 3x10^3 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 84 (Cohort 1 only) | 75.8 Percentage of Participants |
| 3x10^3 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 28 | 76.2 Percentage of Participants |
| 3x10^3 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 14 | 9.5 Percentage of Participants |
| 3x10^3 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 7 | 0 Percentage of Participants |
| 3x10^3 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Any time postvaccination | 89.1 Percentage of Participants |
| 3x10^3 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 360 | 77.4 Percentage of Participants |
| 3x10^3 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 56 | 79.4 Percentage of Participants |
| 3x10^4 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 28 | 70.5 Percentage of Participants |
| 3x10^4 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 14 | 13.6 Percentage of Participants |
| 3x10^4 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 360 | 78.8 Percentage of Participants |
| 3x10^4 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 180 | 81.0 Percentage of Participants |
| 3x10^4 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 84 (Cohort 1 only) | 72.1 Percentage of Participants |
| 3x10^4 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 56 | 70.5 Percentage of Participants |
| 3x10^4 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Any time postvaccination | 88.5 Percentage of Participants |
| 3x10^4 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 7 | 0 Percentage of Participants |
| 3x10^5 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 14 | 42.9 Percentage of Participants |
| 3x10^5 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 28 | 87.5 Percentage of Participants |
| 3x10^5 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 360 | 82.1 Percentage of Participants |
| 3x10^5 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Any time postvaccination | 96.9 Percentage of Participants |
| 3x10^5 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 180 | 88.5 Percentage of Participants |
| 3x10^5 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 7 | 1.6 Percentage of Participants |
| 3x10^5 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 84 (Cohort 1 only) | 88.9 Percentage of Participants |
| 3x10^5 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 56 | 89.1 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 14 | 52.4 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 84 (Cohort 1 only) | 90.3 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 7 | 1.6 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 360 | 93.0 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Any time postvaccination | 98.4 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 28 | 93.7 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 180 | 91.9 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 56 | 93.7 Percentage of Participants |
| Placebo: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 14 | 0 Percentage of Participants |
| Placebo: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 28 | 0 Percentage of Participants |
| Placebo: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 56 | 0 Percentage of Participants |
| Placebo: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 7 | 0 Percentage of Participants |
| Placebo: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 84 (Cohort 1 only) | 4.0 Percentage of Participants |
| Placebo: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 180 | 0 Percentage of Participants |
| Placebo: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 360 | 0 Percentage of Participants |
| Placebo: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Any time postvaccination | 4.0 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 14 | 45.0 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 7 | 0 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Any time postvaccination | 100.0 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 56 | 90.0 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 180 | 94.4 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 28 | 85.0 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 360 | 94.4 Percentage of Participants |
| 9x10^6 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 56 | 93.2 Percentage of Participants |
| 9x10^6 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 7 | 2.2 Percentage of Participants |
| 9x10^6 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 180 | 95.2 Percentage of Participants |
| 9x10^6 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 28 | 91.1 Percentage of Participants |
| 9x10^6 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 360 | 84.6 Percentage of Participants |
| 9x10^6 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 14 | 55.6 Percentage of Participants |
| 9x10^6 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Any time postvaccination | 97.8 Percentage of Participants |
| 2x10^7 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Any time postvaccination | 100.0 Percentage of Participants |
| 2x10^7 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 7 | 2.2 Percentage of Participants |
| 2x10^7 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 56 | 95.7 Percentage of Participants |
| 2x10^7 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 180 | 95.2 Percentage of Participants |
| 2x10^7 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 360 | 97.5 Percentage of Participants |
| 2x10^7 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 14 | 71.1 Percentage of Participants |
| 2x10^7 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 28 | 95.7 Percentage of Participants |
| 1x10^8 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 28 | 100.0 Percentage of Participants |
| 1x10^8 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 180 | 100.0 Percentage of Participants |
| 1x10^8 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 7 | 2.2 Percentage of Participants |
| 1x10^8 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 56 | 97.8 Percentage of Participants |
| 1x10^8 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Any time postvaccination | 100.0 Percentage of Participants |
| 1x10^8 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 360 | 100.0 Percentage of Participants |
| 1x10^8 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 14 | 81.8 Percentage of Participants |
| Placebo: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 28 | 5.0 Percentage of Participants |
| Placebo: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 7 | 0 Percentage of Participants |
| Placebo: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 180 | 5.0 Percentage of Participants |
| Placebo: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 14 | 0 Percentage of Participants |
| Placebo: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 360 | 5.3 Percentage of Participants |
| Placebo: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Day 56 | 0 Percentage of Participants |
| Placebo: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV Neutralizing Antibodies | Any time postvaccination | 10.0 Percentage of Participants |
Secondary
Percentage of Participants With Seroconversion for ZEBOV-specific IgG
Blood was drawn on Days 7, 14, 28, 56, 84 (Cohort 1 only), 180, and 360 days to assess the GMTs via ELISA. Seroconversion was defined as a post-vaccination titer ≥ 200 ELISA Units/mL that was also at least a 4-fold increase in titer compared to baseline.
Time frame: 7, 14, 28, 56, 84 (Cohort 1 only), 180, and 360 days postvaccination
Population: All participants who were vaccinated, had endpoint titer results on Days 0 (baseline) and 28 (relative Days 24-35), and who did not have any protocol violations that influenced interpretation of immunogenicity endpoints. A subset of 25 placebo recipients in Cohort 1 were prospectively identified for testing of immunogenicity endpoints.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| 3x10^3 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 56 | 85.7 Percentage of Participants |
| 3x10^3 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Any time postvaccination | 89.1 Percentage of Participants |
| 3x10^3 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 14 | 11.5 Percentage of Participants |
| 3x10^3 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 360 | 78.4 Percentage of Participants |
| 3x10^3 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 28 | 82.8 Percentage of Participants |
| 3x10^3 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 7 | 0 Percentage of Participants |
| 3x10^3 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 180 | 82.0 Percentage of Participants |
| 3x10^3 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 84 | 81.7 Percentage of Participants |
| 3x10^4 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 56 | 86.9 Percentage of Participants |
| 3x10^4 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 14 | 20.3 Percentage of Participants |
| 3x10^4 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 360 | 75.0 Percentage of Participants |
| 3x10^4 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 180 | 75.9 Percentage of Participants |
| 3x10^4 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Any time postvaccination | 90.2 Percentage of Participants |
| 3x10^4 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 7 | 1.7 Percentage of Participants |
| 3x10^4 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 84 | 85.2 Percentage of Participants |
| 3x10^4 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 28 | 80.3 Percentage of Participants |
| 3x10^5 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Any time postvaccination | 93.8 Percentage of Participants |
| 3x10^5 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 56 | 92.2 Percentage of Participants |
| 3x10^5 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 84 | 87.3 Percentage of Participants |
| 3x10^5 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 7 | 0 Percentage of Participants |
| 3x10^5 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 14 | 20.6 Percentage of Participants |
| 3x10^5 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 28 | 89.1 Percentage of Participants |
| 3x10^5 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 360 | 80.4 Percentage of Participants |
| 3x10^5 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 180 | 83.6 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 84 | 93.4 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 28 | 93.7 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 360 | 89.5 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 14 | 50.0 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 180 | 89.9 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 56 | 93.7 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 7 | 0 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Any time postvaccination | 96.8 Percentage of Participants |
| Placebo: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 56 | 0 Percentage of Participants |
| Placebo: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 84 | 0 Percentage of Participants |
| Placebo: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 7 | 0 Percentage of Participants |
| Placebo: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 28 | 0 Percentage of Participants |
| Placebo: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 14 | 0 Percentage of Participants |
| Placebo: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 360 | 0 Percentage of Participants |
| Placebo: Cohort 1 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Any time postvaccination | 0 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 28 | 90.0 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 180 | 94.4 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Any time postvaccination | 100.0 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 7 | 0 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 360 | 94.4 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 14 | 40.0 Percentage of Participants |
| 3x10^6 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 56 | 90.0 Percentage of Participants |
| 9x10^6 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 56 | 93.2 Percentage of Participants |
| 9x10^6 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 28 | 91.1 Percentage of Participants |
| 9x10^6 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 180 | 90.2 Percentage of Participants |
| 9x10^6 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 14 | 54.5 Percentage of Participants |
| 9x10^6 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 360 | 89.5 Percentage of Participants |
| 9x10^6 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 7 | 0 Percentage of Participants |
| 9x10^6 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Any time postvaccination | 97.8 Percentage of Participants |
| 2x10^7 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Any time postvaccination | 97.8 Percentage of Participants |
| 2x10^7 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 360 | 97.4 Percentage of Participants |
| 2x10^7 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 28 | 93.5 Percentage of Participants |
| 2x10^7 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 180 | 97.6 Percentage of Participants |
| 2x10^7 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 7 | 2.2 Percentage of Participants |
| 2x10^7 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 14 | 81.8 Percentage of Participants |
| 2x10^7 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 56 | 97.8 Percentage of Participants |
| 1x10^8 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 180 | 97.6 Percentage of Participants |
| 1x10^8 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Any time postvaccination | 97.8 Percentage of Participants |
| 1x10^8 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 28 | 95.6 Percentage of Participants |
| 1x10^8 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 360 | 93.2 Percentage of Participants |
| 1x10^8 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 7 | 2.2 Percentage of Participants |
| 1x10^8 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 56 | 97.8 Percentage of Participants |
| 1x10^8 Pfu V920: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 14 | 72.7 Percentage of Participants |
| Placebo: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Any time postvaccination | 5.0 Percentage of Participants |
| Placebo: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 180 | 0 Percentage of Participants |
| Placebo: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 14 | 0 Percentage of Participants |
| Placebo: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 56 | 0 Percentage of Participants |
| Placebo: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 7 | 0 Percentage of Participants |
| Placebo: Cohort 2 | Percentage of Participants With Seroconversion for ZEBOV-specific IgG | Day 28 | 5.0 Percentage of Participants |